Lewis became Chief Executive Officer of Evestia Clinical in December 2024 upon its initial investment in the acquisition of EMAS Pharma. He has over 25 years’ experience in preclinical and clinical drug development with organizations ranging from emerging biotech firms to a number of clinical stage contract research organizations (CROs). He has been involved in all phases of drug development, with a strong focus on oncology, rare diseases and other key therapeutic areas.
A seasoned senior executive, Lewis has a proven track record of driving operational excellence and commercial success in complex and evolving market environments. His leadership has consistently delivered impactful business transformations and strategic growth.
Lewis holds a bachelor’s degree from the University of Edinburgh, a master’s in biotechnology from the University of Reading, and an MBA from Instituto de Empresa in Madrid.
Lewis began his career at Microbiology MLSA and has since held several senior leadership positions. Notably, he served as a senior executive at Covance and as a board member and senior executive at Chiltern International, Ergomed, and as Head of Global Medical Affairs at Medcann. His leadership across these roles has contributed to the achievement of numerous business transformations and strategic milestones.
Partner With Us
When every decision matters, we make sure you get them right.
